Achmea Investment Management B.V. Has $23.09 Million Stake in Quest Diagnostics Incorporated (NYSE:DGX)

Achmea Investment Management B.V. reduced its holdings in Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 1.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 136,466 shares of the medical research company's stock after selling 1,680 shares during the quarter. Achmea Investment Management B.V. owned approximately 0.12% of Quest Diagnostics worth $23,090,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Bruce G. Allen Investments LLC grew its holdings in shares of Quest Diagnostics by 57.8% during the first quarter. Bruce G. Allen Investments LLC now owns 183 shares of the medical research company's stock worth $31,000 after purchasing an additional 67 shares during the last quarter. Golden State Wealth Management LLC grew its holdings in Quest Diagnostics by 157.3% during the 1st quarter. Golden State Wealth Management LLC now owns 193 shares of the medical research company's stock worth $33,000 after acquiring an additional 118 shares during the last quarter. NBC Securities Inc. bought a new stake in Quest Diagnostics during the 1st quarter worth about $35,000. Continuum Advisory LLC increased its position in Quest Diagnostics by 11,100.0% in the 1st quarter. Continuum Advisory LLC now owns 224 shares of the medical research company's stock valued at $38,000 after acquiring an additional 222 shares in the last quarter. Finally, SBI Securities Co. Ltd. bought a new position in shares of Quest Diagnostics in the fourth quarter worth about $54,000. 88.06% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Redburn Atlantic assumed coverage on shares of Quest Diagnostics in a research report on Wednesday, April 2nd. They issued a "buy" rating and a $195.00 price objective for the company. Truist Financial lifted their target price on Quest Diagnostics from $182.00 to $190.00 and gave the company a "hold" rating in a research note on Wednesday, April 23rd. Evercore ISI upped their price target on Quest Diagnostics from $175.00 to $180.00 and gave the company an "in-line" rating in a research note on Wednesday, April 23rd. JPMorgan Chase & Co. lifted their price objective on Quest Diagnostics from $180.00 to $190.00 and gave the stock a "neutral" rating in a research report on Tuesday, May 6th. Finally, Piper Sandler upped their target price on shares of Quest Diagnostics from $180.00 to $200.00 and gave the company a "neutral" rating in a research report on Monday, April 28th. Eight investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $185.73.

Insiders Place Their Bets

In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 2,555 shares of the business's stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $170.00, for a total transaction of $434,350.00. Following the transaction, the senior vice president now owns 10,575 shares of the company's stock, valued at $1,797,750. The trade was a 19.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Mark E. Delaney sold 874 shares of the stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $175.72, for a total value of $153,579.28. Following the completion of the sale, the senior vice president now directly owns 8,372 shares of the company's stock, valued at approximately $1,471,127.84. The trade was a 9.45% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 42,620 shares of company stock valued at $7,190,045 in the last quarter. 8.16% of the stock is currently owned by insiders.

Quest Diagnostics Stock Down 0.9%

Quest Diagnostics stock opened at $177.10 on Friday. The company has a 50 day moving average of $175.49 and a 200-day moving average of $166.81. The company has a quick ratio of 1.31, a current ratio of 1.44 and a debt-to-equity ratio of 0.84. Quest Diagnostics Incorporated has a twelve month low of $135.47 and a twelve month high of $182.38. The stock has a market capitalization of $19.77 billion, a PE ratio of 22.39, a price-to-earnings-growth ratio of 2.49 and a beta of 0.49.

Quest Diagnostics (NYSE:DGX - Get Free Report) last released its quarterly earnings results on Tuesday, April 22nd. The medical research company reported $2.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.15 by $0.06. The firm had revenue of $2.65 billion for the quarter, compared to the consensus estimate of $2.63 billion. Quest Diagnostics had a return on equity of 15.11% and a net margin of 8.81%. On average, equities research analysts anticipate that Quest Diagnostics Incorporated will post 9.7 EPS for the current fiscal year.

Quest Diagnostics Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, July 21st. Shareholders of record on Monday, July 7th will be given a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a yield of 1.81%. The ex-dividend date of this dividend is Monday, July 7th. Quest Diagnostics's dividend payout ratio (DPR) is currently 40.46%.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.